Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Board changes

30 May 2024 12:00

RNS Number : 4436Q
Xaar PLC
30 May 2024
 

30 May 2024

 

Xaar plc

 

Board changes

 

Xaar plc ("Xaar" or "the Group" or "the Company"), the leading inkjet printing technology group, is pleased to announce the appointment of Dr Inken Braunschmidt as Independent Non-Executive Director.

 

Inken joins the Board with effect from 1 June 2024 and on appointment will be a member of the Audit, Remuneration and Nomination Committees.

 

As previously disclosed, Alison Littley had notified the Board of her intention to step down as a Non-Executive Director of the Company during 2024. It is now confirmed that Alison will leave the Board on 30 June 2024. Inken will be appointed as Chair of Remuneration Committee on 1 July 2024.

 

Richard Amos, Non-Executive Director, will replace Alison Littley as the Company's Senior Independent Director on 1 July 2024.

 

Inken Braunschmidt is currently a non-executive director of James Fisher and Sons plc, listed on the London Stock Exchange, and Chair of its Remuneration Committee as well as a member of the Audit and Nomination Committees. She was Chief Innovation and Digital Officer and member of the Executive Board of Halma plc until 2023. Prior to joining Halma plc in 2017, Inken spent 13 years at RWE AG, the German energy giant, and its renewables subsidiary innogy SE, where she held various international leadership roles focusing on strategy, innovation, digital transformation and change management. Inken studied Business Administration, Innovation & Technology Management at Kiel University and did her PhD thesis in Technology Management. Inken is member of the Digital Programme Board of the Royal Academy of Engineering.

 

 

Andrew Herbert, Chairman, commented:

 

"We are delighted to welcome Inken to the Board and her expertise and experience in international electronic engineering and digital innovation and transformation are very relevant to the opportunities and challenges that face Xaar. I would like to thank Alison for her contribution and commitment to the Board of Xaar as a director since 2020 and wish her the very best for the future."

 

The Company confirms there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointment of Inken Braunschmidt.

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAURAWRSAUVORR
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.